Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (0.9% NaCl) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

NCT03232567
View directory record Official record
Conditions
Influenza
Interventions
NasoVAX
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

NCT03623022
View directory record Official record
Conditions
Healthy
Interventions
Clinical Center Reference Endotoxin (CCRE), Normal saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months to 11 Years
Enrollment
11,942 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 9, 2026, 6:20 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty

NCT02570503
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Ropivacaine, Ketorolac, Clonidine, Epinephrine, 0.9% sodium chloride
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali

NCT02334462
View directory record Official record
Conditions
Malaria
Interventions
Pfs230D1M-EPA/Alhydrogel, Pfs25M-EPA/Alhydrogel, TWINRIX, Menactra
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

NCT01590446
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Normal Saline
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
22 Years to 45 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

NCT01690988
View directory record Official record
Conditions
Delirium
Interventions
Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Not applicable Interventional

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

NCT00623688
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer
Device
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 9, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block (SGB) For Women for Breast Cancer

NCT02513329
View directory record Official record
Conditions
Hot Flushes, Hot Flashes
Interventions
Bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 1 Interventional

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

NCT00527761
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Cisplatin, Docetaxel, Temodar
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 9, 2026, 6:20 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829
View directory record Official record
Conditions
Knee Osteoarthritis, Synovitis of Knee
Interventions
4P004, Placebo (NaCl 0.9%)
Drug
Lead sponsor
4Moving Biotech
Industry
Eligibility
40 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Tucson, Arizona • Chicago, Illinois • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 9, 2026, 6:20 AM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 9, 2026, 6:20 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Metabolic Effects of Natriuretic Peptide Hormones

NCT03397966
View directory record Official record
Conditions
Obesity, Cardiovascular Physiological Phenomena, Metabolism
Interventions
recombinant human BNP(1-32), placebo (control, normal saline)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
View directory record Official record
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714
View directory record Official record
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Non-myeloablative Stem Cell Transplantation
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 9, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Results available

Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury

NCT05058677
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
aerosolized 2% lidocaine (20mg/ml), instilled 0.9% sodium chloride (NS), instilled 2% lidocaine solution, Endotracheal Suctioning (ETS)
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 16 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 9, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional Results available

IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis

NCT02241512
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Ibuprofen, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 9, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Results available

The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy

NCT05480111
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Local anesthesia at incision site, Sham QL, Sham Local, QL
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 9, 2026, 6:20 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation

NCT02802436
View directory record Official record
Conditions
Healing of Extraction Socket
Interventions
Extraction with socket graft
Procedure
Lead sponsor
Boston University
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 9, 2026, 6:20 AM EDT
Recruiting Phase 4 Interventional

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

NCT06860711
View directory record Official record
Conditions
Chronic Kidney Disease, Pediatric Urology
Interventions
NSAIDs, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Months to 25 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 9, 2026, 6:20 AM EDT